RudaCure Inc. (CEO Yongho Kim), a global 疼痛治疗 company, announced on the 11th that it will present its next-generation 疼痛治疗药 管线 research results at the 神经科学学会 (SfN) Annual Meeting in 圣迪亚哥, USA on the 19th.
Through this presentation, RudaCure will disclose pre临床数据 on its dual-target 创新药物候选物 that simultaneously modulates TRPV1 and MOR (Mu阿片受体).
According to RudaCure, the candidate demonstrated excellent 镇痛疗效 in various 神经性疼痛 动物模型 including 糖尿病周围神经病变 (DPN) and 化疗引起的周围神经病变 (CIPN). In the 骨关节炎 (OA) model, it showed not only 疼痛缓解 but also tissue damage inhibition and cartilage protective effects.
RudaCure emphasized that this candidate overcomes the fever 副作用 commonly reported with TRPV1-class drugs and the 成瘾性/耐药性 issues of MOR agonists, achieving both 疗效 and safety. The company is accelerating IND-enabling studies for Phase 1 临床试验 based on these results.
CEO Yongho Kim stated, "We will present the innovative potential of our next-generation 疼痛治疗药 at the world's largest neuroscience conference," adding, "We plan to actively advance global partnerships based on RCI002's differentiated 作用机制."
